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In the previous issue of Critical Care, Tang and colleagues 
[1] oﬀ  er a very novel systematic review of 12 studies of 
gene expression in blood of humans who have sepsis. Th  e 
studies conclude that there was no discernable transition 
from a pro- to an anti-inﬂ  ammatory expression pheno-
type in whole blood in human sepsis. Th   e authors posit 
that sepsis as a pro-inﬂ  ammatory phenotype that shifts 
to an anti-inﬂ  ammatory phenotype may be ﬂ  awed. Th  is 
provocative conclusion disagrees with the evidence 
(animal and clinical); furthermore, ongoing translational 
and clinical studies hinge on the premise that there is 
indeed a transition (at about days 3 to 5 of clinical sepsis) 
from a brisk pro-inﬂ  ammatory to an anti-inﬂ  ammatory 
phenotype.
Th  e innate immune system is the ‘hard-wired’ rapid 
response system of each individual [2]. Th  e  ﬁ  rst step in 
recognition of microorganisms is that pattern recognition 
receptors (such as the Toll-like receptor family) bind to 
highly conserved molecules called pathogen-associated 
molecular proteins. Accordingly, Tang and colleagues [1] 
found that upregulation of pathogen recognition recep-
tors and signal transduction pathways was a consistent 
theme in expression studies.
Th  e review by Tang and colleagues [1] has strengths, 
including deﬁ   ned screening criteria, broad literature 
review, strict inclusion criteria, and transparent methods 
for assessing strengths and weaknesses of studies to say 
nothing of the research strengths of the authors. Further-
more, the summary is presented in clear tables accessible 
to expert and non-expert readers alike.
Th   ere are other issues to consider in the review. First, 
one source of variation in gene expression studies in 
sepsis is variability in time from onset of sepsis to time of 
blood draw. Th  e authors found no obvious pattern to 
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However, the only studies that can be sure of onset of 
sepsis are the human endotoxemia studies (because time 
of endotoxin administration is known). I do not think 
that there are enough studies of expression at diﬀ  erent 
times; thus, the authors’ conclusion may be premature 
(but could be proven correct by studies designed to 
address this important hypothesis).
Another source of variation of gene expression is 
variability of tissue examined given that diﬀ  erent tissues 
express diﬀ  erent genes at the same time in sepsis. Whole 
blood is a mélange of tissues (a variety of leukocytes); 
therefore, one assesses a weighted sum of all leukocyte 
classes. Furthermore, leukocyte diﬀ  erential  changes 
rapidly in sepsis; thus, variability in whole-blood gene 
expression over time could be confounded by changes in 
leukocyte diﬀ  erential. About half of the studies assessed 
peripheral mononuclear cells [3-8].
A third great source of variable gene expression in 
sepsis is heterogeneity of causes and microbiology of 
sepsis, yet expression may vary according to cause and 
microbiology. For example, only one study [9] compared 
Gram-positive with Gram-negative sepsis. None com-
pared various community-acquired infections (for exam-
ple, pneumonia versus peritonitis).
Th   ere are concerns regarding the quality of data in gene 
expression [10,11]. Only three of these studies conﬁ  rmed 
microarray data with an independent measurement of 
expression.
One interpretation of the summary in Table 4 is that 
the one study of pre-sepsis [12] found increased expres-
sion of pro-inﬂ  ammatory genes and two of three studies 
of early sepsis ([7] and [13] but not [5]) found increased 
expression of pro-inﬂ   ammatory genes. In contrast, in 
studies of late sepsis, three of six studies found increased 
expression of pro-inﬂ  ammatory genes [8,14,15] whereas 
three of six studies found decreased expression of pro-
inﬂ  ammatory genes [9,14,16]. Th   us, there is very limited 
evidence that there is early pro-inﬂ  ammatory  gene 
expression and then later, balanced pro- and anti-
inﬂ  ammatory gene expression.
Th   e balance of pro- to anti-inﬂ  ammatory gene expres-
sion is diﬃ   cult to quantify. Do any studies attempt to 
quanti  tate a ratio of pro- to anti-inﬂ  ammatory  gene 
expression? Even such a simplistic approach ignores 
diﬀ   er  ing potency of diﬀ   erent proteins. Is threefold 
expression of tumor necrosis factor-alpha really balanced 
biologically by threefold expression of interleukin-10?
Sample size is highly variable in the studies (n = 12 to 
176) reviewed by Tang and colleagues [1]. Sample size is 
clearly important, especially in studies with many 
outcome variables (gene expression levels). We need to 
know how often power and sample size were calculated 
and how often statistical power was adequate with 
adjustments for multiple comparisons. Th   is is important 
since the main story of Tang and colleagues [1] is 
negative: there is no evidence of a clear pro- and then 
anti-inﬂ  ammatory pattern of gene expression. Yet this 
could be a false negative if the studies were under-
powered for such a question.
I agree with Tang and colleagues [1] that the variability 
in the quality of statistical methods in studies of gene 
expression in human sepsis is very important and deserves 
more emphasis in the literature and in reviews such as that 
of Tang and colleagues. Most non-expert readers need a 
deeper explanation of the statistical methods that are 
desirable and how these vary across studies.
Interestingly, Tang and colleagues do not comment on 
how therapies alter gene expression in sepsis [17].
In my opinion, the above limitations of studies and the 
authors’ summary of the literature require a leap of faith 
to suggest that the paradigm of sepsis as a pro-
inﬂ  ammatory phenotype that shifts to an anti-inﬂ  am  ma-
tory phenotype is fundamentally ﬂ  awed. In other words, 
the absence of evidence in these expression studies is not 
the same as having well-conducted studies with clear 
negative evidence. While Tang and colleagues may be on 
the right route, they have not reached the summit. Th  ere 
are tough and perhaps impassable cruxes ahead.
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